Clinical Trial Update: Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

This Phase 3 trial assessed the efficacy and safety of three doses of vildagliptin in drug-naive adults with Type 2 diabetes. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Galvus (vildagliptin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED